Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Alembic Pharmaceuticals Limited

NSE: APLLTDPharmaceuticals

Share price

₹800.50

-3.99% close of 8 Oct 2026

Market cap ₹15,610 CrP/E 20.9

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 7 Oct 2026, the close above is 8 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

68

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹15,610 Cr

P/E ratio

20.9

P/B ratio

2.8

ROCE

12.6%

ROE

13.5%

Dividend yield

1.4%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹960.7052-week low ₹646.55

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 14.1% over the past year, and 12.7% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 12.1% to 15.0% over the last four years.

Whether it grew faster than its sector

It grew 12.7% a year against a sector median of 13.1% — 0.4 percentage points slower.

Room to re-rate, or risk of de-rating

At 20.9× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 27.8×, the 18th percentile of its own range.

Whether growth justifies the valuation

Priced at 0.7 times its growth rate, on earnings growth of 28%.

Profit growthPrice per ₹1 profitPer 1% growth
Alembic Pharmaceuticals Limited — this one28%/yr20.9×₹0.75
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 76 of 130 on returns, 56 of 127 on growth, 80 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 12.6% on capital, ahead of 42% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹2950 crore of cash from the business, spent ₹2229 crore on plant and equipment, and returned ₹637 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 105 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back more slowly than it used to: it went from being waiting 74 days for its cash to waiting 87 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 9 checks clear · 78%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue grew 26% and management raised FY27 growth outlook toward the mid-teens.

Announced 4 Aug 2026 · Consolidated · Unaudited

Revenue

₹2,150 Cr

Revenue vs last year

+25.6%

Revenue vs last quarter

+16.3%

Net profit

₹172 Cr

Profit vs last year

+11.9%

Profit vs last quarter

-14.7%

Net margin

8.0%

EPS

₹8.80

Earnings call transcript · 4 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹15,610 Cr
Prev close
₹800.50
52w High
₹998
52w Low
₹636
Enterprise value
₹16,963 Cr
Beta
0.8
Price CAGR 1y
-9.0%
Price CAGR 3y
3.0%
Price CAGR 5y
1.0%
Price CAGR 10y
2.0%

Ratios

Return on assets
7.7%
PEG ratio
0.8
P/E ratio
20.9
P/B ratio
2.8
EV / EBITDA
15.3
Industry P/E
38.0
ROCE
12.6%
ROCE 5y average
11.4%
ROE
13.5%
Debt / Equity
0.3
Interest coverage
8.4
Dividend yield
1.4%
ROE 3y average
13.0%
ROE last year
13.0%

Annual P&L

Annual revenue
₹7,345 Cr
Annual profit
₹671 Cr
Operating margin
15.0%
Net profit margin
9.1%
EBITDA margin
15.3%
Sales growth 3y
9.1%
Sales growth 5y
6.4%
Profit growth 3y
28.0%
Profit growth 5y
-9.0%
EPS
₹34.3
Sales growth TTM
14.0%
Profit growth TTM
26.0%
Dividend payout
35.0%

Quarter P&L

Sales latest quarter
₹2,150 Cr
Profit latest quarter
₹172 Cr
YoY quarterly sales growth
25.7%
YoY quarterly profit growth
11.7%
OPM latest quarter
15.4%

Balance Sheet

Book Value
₹291
Face Value
₹2.0
Total debt
₹1,430 Cr
Total cash
₹203 Cr
Borrowings
₹1,430 Cr
Reserves / Equity
144.5

Cash Flow

Operating cash flow
₹783 Cr
Free cash flow
₹290 Cr
FCF yield
1.3%
Net cash flow
₹113 Cr

Shareholding

Promoter holding
69.9%
FII holding
4.2%
DII holding
15.9%
Public holding
10.0%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.94,28,0570.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.52,54,6650.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.31,79,1640.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,14,9630.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.31,10,6990.10362.1125.52,026.329.117.8
Cipla1,327.2029.91,06,9970.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.71,03,8760.04574.129.64,030.612.913.5
Alembic Pharma833.8022.016,3951.44172.412.12,149.825.712.6
Median417.9034.42,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,4861,5951,6311,5171,5621,6481,6931,7701,7111,9101,8761,8482,150
Expenses1,2871,3871,3641,2571,3251,4091,4331,4981,4301,5941,5851,6201,818
Material Cost426431463449404517
Change in Inventories12-133-74-63-1.88-18
Purchases of Stock-in-Trade93109127143130121
Employee Cost394423438433439474
Other Expenses574599641621649724
Operating Profit199208266260237239260271281316292228332
OPM %13131617151515151617161215
Other Income121034230101468-27215
Exceptional items (within Other Income)000-42-250
Interest14161511131922252424232328
Depreciation66686969697170697476808998
Profit before tax130135185183157180178192190224162119222
Tax %7-12314152318191818-7022
Net Profit121137180178135153138157154184132202172
EPS in Rs6.146.959.189.076.857.807.047.987.859.406.76108.80
Diluted EPS in Rs7.987.859.406.76108.80

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2,0563,1663,1053,1313,9354,6065,3935,3065,6536,2296,6727,3457,784
Expenses1,6532,1592,4902,4883,0613,3833,9134,4324,9705,2965,6646,2246,617
Material Cost1,6721,747
Change in Inventories-290-272
Purchases of Stock-in-Trade411509
Employee Cost1,5621,732
Other Expenses2,3082,510
Operating Profit4031,0076156438741,2231,4808746829321,0081,1211,167
OPM %20322021222727161215151515
Other Income47279-398756-22856-14-1
Exceptional items (within Other Income)13-67
Interest4553182716185056799498
Depreciation447283105115157183287275273279319342
Profit before tax3599365295417491,0001,368625355632707694726
Tax %212323222120191743183
Net Profit2837204034135838011,146521342616582671690
EPS in Rs15382122314458271731303435
Diluted EPS in Rs3034
Dividend Payout %23919181823243846353735

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
9%
5 years
6%
3 years
9%
TTM
14%

Compounded profit growth

10 years
0%
5 years
-9%
3 years
28%
TTM
26%

Stock price CAGR

10 years
2%
5 years
1%
3 years
3%
1 year
-9%

Return on equity

10 years
16%
5 years
11%
3 years
13%
Last year
13%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital383838383838393939393939
Reserves8471,5601,8652,1822,6813,1825,0285,1984,3314,7795,1525,636
Borrowings264114897081,1281,7475847177225131,2581,430
Other Liabilities4937186981,0139311,0221,0581,1671,0901,1141,3251,658
Minority Interest-1.42-5.83
Total Liabilities1,6412,4292,6893,9414,7785,9896,7097,1226,1836,4467,7738,763
Fixed Assets5477087999931,1581,5521,7881,7982,3982,5472,5243,081
CWIP83933961,0101,5511,8462,1832,304601524837683
Investments287504249182361189693127141
Other Assets1,0091,5411,4441,8962,0192,5732,5022,9023,0873,2814,2854,858
Total Assets1,6412,4292,6893,9414,7785,9896,7097,1226,1836,4467,7738,763

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1729483293128124491,46355272480388783
Cash from Investing Activity-256-307-486-884-756-731-840-372-448-321-568-506
Cash from Financing Activity87-224-12950359155-597-217-262-438444-164
Net Cash Flow3417-286-69115-12726-371445-37113
Free Cash Flow-52647348-49549-285804128282487-466290

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days644040614569245668607773
Inventory Days196266269302356417431406315350466462
Days Payable166264213313237220194178145157179154
Cash Conversion Cycle94429651164266261283237253363381
Working Capital Days323661692450737477888787
ROCE %38662922232426117131313

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters707070707070707070707070
FIIs4.514.524.464.323.944.173.943.964.044.234.264.17
DIIs141515151616161616161616
Public1211111110109.969.919.929.849.8310
No. of Shareholders89,55285,21276,56774,82991,42993,94491,33689,01389,96987,00086,43286,796

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -13.9% (₹929.95 → ₹800.50)Brick size ₹26.38 (fixed)Bricks 18
₹700₹900₹801Nov '25Feb '26Jun '26
Price moved up one brickPrice moved down one brickLast close ₹800.50 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

R&D as % of revenue

9.00pct

2026-06-30

FY revenue / permanent employees + workers, same basis (calc)

38,57,214inr

2026-03-31

News

News and filings about Alembic Pharmaceuticals Limited. Open one to see why it matters.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Active Pharmaceutical Ingredients (APIs)
  • Intermediate reagents / key starting materials
  • Packaging materials

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE901L01018

Plants

  • API I & II - Panelav
  • API III - Karkhadi
  • Aleor Dermaceuticals Facility - Karkhadi
  • F1 - Panelav Formulation Facility
  • F2 - Panelav Oncology Facility
  • F3 - Karkhadi Formulation Facility
  • F4 - Jarod Formulation Facility
  • Pithampur Formulation Facility
  • Sikkim Formulation Facility

News impact

Big market events that reach Alembic Pharmaceuticals Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

29 Jul 2026unspecified₹12
29 Jul 2025unspecified₹11
15 Jul 2024unspecified₹11
28 Jul 2023unspecified₹8
17 Aug 2022interim₹10
19 Jul 2021unspecified₹14
16 Mar 2020special₹3
16 Mar 2020interim₹7

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.